| Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells L Gu, Y Zhu, M Lee, A Nguyen, NT Ryujin, JY Huang, SK Pandit, ... Proceedings of the National Academy of Sciences 120 (19), e2300706120, 2023 | 22 | 2023 |
| Systemic neoadjuvant and adjuvant therapies in the management of hepatocellular carcinoma—a narrative review S Chamseddine, M LaPelusa, AO Kaseb Cancers 15 (13), 3508, 2023 | 13 | 2023 |
| Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients YI Mohamed, DG Duda, MO Awiwi, SS Lee, L Altameemi, L Xiao, ... Oncotarget 13, 1314, 2022 | 10 | 2022 |
| A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma L Balcar, B Scheiner, CAM Fulgenzi, A D’Alessio, K Pomej, MB Roig, ... JHEP reports 6 (2), 100982, 2024 | 8 | 2024 |
| Hassan B Mohamed, DG Duda, MO Awiwi, SS Lee, L Altameemi, L Xiao, ... Can Science Save Africa, 2001 | 7 | 2001 |
| Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study V Joerg, B Scheiner, CAM Fulgenzi, M Schönlein, L Kocheise, AW Lohse, ... Hepatology Communications 7 (11), e0302, 2023 | 4 | 2023 |
| The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma B Gok Yavuz, S Datar, S Chamseddine, YI Mohamed, M LaPelusa, ... Cancers 15 (19), 4875, 2023 | 4 | 2023 |
| Mycobacterium ulcerans lung infection in an immunocompetent patient S Chamseddine, JR Hindy, SF Haddad, SS Kanj BMJ Case Reports CP 15 (8), e250547, 2022 | 3 | 2022 |
| Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma S Chamseddine, YI Mohamed, SS Lee, JC Yao, ZI Hu, HS Tran Cao, ... Oncology 101 (11), 730-737, 2023 | 2 | 2023 |
| Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma S Chamseddine, BG Yavuz, YI Mohamed, SS Lee, JC Yao, ZI Hu, ... Journal of Immunotherapy and Precision Oncology 7 (4), 255-262, 2024 | 1 | 2024 |
| Circulating tumor DNA (ctdna) as a biomarker of response to therapy in advanced hepatocellular carcinoma treated with nivolumab YI Mohamed, SS Lee, T Demir, S Chamseddine, ZI Hu, L Xiao, K Elsayes, ... Cancer Biomarkers 41 (1), 83-91, 2024 | 1 | 2024 |
| Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma S Chamseddine, M LaPelusa, L Xiao, YI Mohamed, SS Lee, ZI Hu, ... Journal of Hepatocellular Carcinoma, 455-461, 2024 | | 2024 |
| Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report S Chamseddine, M LaPelusa, K Carter, V Nguyen, YI Mohamed, Y Sakr, ... Journal of Gastrointestinal Oncology 15 (3), 1324, 2024 | | 2024 |
| Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable … MB LaPelusa, S Chamseddine, L Xiao, E Hasanov, P Bhosale, ... Journal of Clinical Oncology 42 (3_suppl), 561-561, 2024 | | 2024 |
| Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma M LaPelusa, S Chamseddine, T Cao, H Sanderson, L Xiao, E Hasanov, ... Oncology, 1-20, 2024 | | 2024 |
| 973P Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients S Lee, S Chamseddine, ZI Hu, A Mahvash, JN Vauthey, HST Cao, ... Annals of Oncology 34, S604, 2023 | | 2023 |
| 961P Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma S Chamseddine, A Kaseb Annals of Oncology 34, S600, 2023 | | 2023 |
| CLINICOPATHOLOGIC AND TREATMENT OUTCOME DATA FROM 165 FIBROLAMELLAR CARCINOMA PATIENTS S Chamseddine, S Lee, A Kaseb HEPATOLOGY 78, S1817-S1817, 2023 | | 2023 |
| Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma–A Narrative Review M LaPelusa, S Chamseddine, AO Kaseb Preprints, 2023 | | 2023 |
| Translational analysis of combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer. SS Lee, F Duan, S Chamseddine, S Jindal, S Basu, S Yadav, J Allison, ... Journal of Clinical Oncology 41 (16_suppl), e16198-e16198, 2023 | | 2023 |
